Posts Tagged ‘Aleix Prat’

Tuesday January 23rd, 2018

Researchers identify a protein that keeps metastatic breast cancer cells dormant

The time needed for breast cancer metastases (secondary lesions caused by cells that have escaped from the original tumour) to develop varies between patients, and little is known about the mechanisms that govern latency (the dormant state of cells that have already spread through the body). A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light on the molecular basis underlying how the expression of certain genes facilitates the spread of metastatic lesions. Dr. Aleix Prat, Head of the Clinical Oncology Department at Hospital Clínic and of the Translational genomics and targeted therapeutics in solid tumors research team at IDIBAPS, has participated in this study. Read the rest of this entry »

Comments Closed
Monday June 12th, 2017

Aleix Prat, named Board Member of the Breast International Group

Dr. Aleix Prat, Head of the Clinical Oncology Department at Hospital Clínic and of the Translational genomics and targeted therapeutics in solid tumors research team at IDIBAPS, has been named member of the Executive Board of the Breast International Group (BIG). The BIG is an international non-profit organisation that includes more than 56 cooperative groups from around the world, more than 10,000 experts and it is linked to more than 3,000 hospitals. Its main goal is to promote clinical and translational research in breast cancer. The appointment, which represents a recognition to his professional career in this field, took place during the annual meeting of the American Society of Clinical Oncology (ASCO) held in June 2-6 in Chicago. Read the rest of this entry »

Comments Closed
Thursday April 20th, 2017

A study reveals the biological changes in breast cancer between the primary tumor and metastases

A study published in the journal Cancer Research underscores the importance of the molecular characterization of the metastases in breast cancer. Researchers have described, for the first time, that the longer the time from the onset of the tumor to the development of metastasis is, the more aggressive this cancer becomes. They have also shown that between the initial tumor and the metastasis the subtype of breast cancer can change in up to 40% of cases. The work has been coordinated by Aleix Prat, Head of the Oncology Department of the Hospital Clínic, Head of the Translational Genomics team and directed therapies in solid tumors IDIBAPS team and Head of the VHIO Translational Genomics Group. The first author of the study is Juan Miguel Cejalvo, PhD student of the PhD4MD program in the group led by Aleix Prat at IDIBAPS and in the Growth Control and Cancer Metastasis group of the Institute for Research in Biomedicine (IRB Barcelona), led by the ICREA researcher Roger Gomis.

Read the rest of this entry »

Comments Closed
Wednesday January 18th, 2017

A diagnostic test for lung cancer detects genetic alterations which may remain hidden when conventional techniques are used

A study led by researchers from Hospital Clínic-IDIBAPS, in collaboration with Dexeus University Hospital, shows the effectiveness of a new genetic test for molecular diagnosis in lung cancer. This is the first time that a test for this type of tumor is implemented in clinical practice. It consists of analyzing three genes with an innovative genomic technology that allows detecting multiple alterations which may not be identified when conventional diagnostic techniques are used. If these genetic alterations are detected, the patient can be treated with an oral drug that has minimal toxicity and a very high clinical benefit. The study has been coordinated by Dr. Noemí Reguart, an oncologist at the Hospital Clínic-IDIBAPS, and Dr. Aleix Prat, head of the Clinical Oncology Department and of the IDIBAPS research team on Translational Genomics and directed therapies in solid tumors.

Read the rest of this entry »

Comments Closed
Wednesday November 30th, 2016

Hospital Clínic will implement a new genomic test to predict response to treatment in breast cancer

Researchers from Hospital Clínic and IDIBAPS lead an international study in which they have developed a genomic test to predict the response to chemotherapy in breast cancer. Hospital Clínic of Barcelona will be the first hospital in the world to implement this third generation test. This test is based on the data produced by the second-generation test PAM50, and for which Hospital Clínic is one of the reference centers. The article, published today in the journal Clinical Cancer Research, has been coordinated by Dr. Aleix Prat, Head of the Clinical Oncology Department at Hospital Clínic, the Translational genomics and targeted therapeutics in solid tumors research team at IDIBAPS and the Translational Genomics group of the Vall d’Hebron Institute of Oncology (VHIO). The study has involved several hospitals in Spain within the GEICAM breast cancer co-operative group, researchers from the University of North Carolina (USA), the Royal Marsden Foundation Trust in London, the University of Otago (New Zealand) and The University of Edinburgh (Scotland).

Read the rest of this entry »

Comments Closed

Categories

Posted in:

Friday September 23rd, 2016

Clínic receives a donation of 50.000 euros for cancer research

Hospital Clínic has received 50,000 euros to be allocated to cancer research by Ms. Núria Klimek. Thanks to this donation, the  IDIBAPS research team Translational Genomics and targeted therapies in solid tumors, led by Dr. Aleix Prat, Chief of the Oncology Department at Clínic, will be strengthen.

Read the rest of this entry »

Comments Closed
Page 1 of 212